Newron Pharmaceuticals is a biopharmaceutical company headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. They are dedicated to developing innovative therapies for patients suffering from diseases of the central and peripheral nervous system. With a strong pipeline of drug candidates at different clinical stages, including Xadago for Parkinson's disease, Evenamide for schizophrenia, and Ralfinamide for specific rare pain indications, Newron is committed to improving the quality of life for individuals with CNS disorders.
Newron Pharmaceuticals' shares are listed on SIX Swiss Exchange, the primary market of the Düsseldorf Stock Exchange, and XETRA. They provide reliable and transparent information about their business to investors, including the latest share price, key financial data, and presentations. With a proven track record of drug development and commercialization, Newron Pharmaceuticals is dedicated to delivering innovative treatments and making a positive impact in the field of CNS drug development.
Generated from the website